News

Roche and Flatiron Health asserted that the two partners have ventured into a definitive agreement enumerating that Roche will acquire all shares of Flatiron  Health from an existing…
Read More...

AbbVie asserted results from the double-blinded extension phase of the Phase 2 CELEST Study, exhibiting that many patients treated with upadacitinib who attained clinical response after…
Read More...

Great Point Partners, LLC submitted a letter to the Board of Directors of BioCryst Pharmaceuticals strongly rebuking BCRX's merger with Idera Pharmaceuticals. The letter states "We…
Read More...

Novartis declared additional results from the SCULPTURE study marking that two thirds of moderate to severe plaque psoriasis patients treated with Cosentyx exhibited zero impact of skin…
Read More...

 Photocure ASA asserted that the U.S Food and Drug Administration approved its supplemental new drug application to extend the indication for Blue Light Cystoscopy with Cysview to…
Read More...

Teva Pharmaceutical Industries asserted the commercial availability of QVAR RediHaler Inhalation Aerosol to patients in both 40 mcg and 80 mcg strengths by prescription in the U.S QVAR…
Read More...

GT Biopharma focused on the development and commercialization of novel cancer immunotherapy products as well as central nervous system treatments asserted the appointment of Shawn M.…
Read More...

Influenza Vaccine is one of the best ways known to protect against the flu. However, because of the severity of this season, there have been questions raised about how well this year's…
Read More...

Arrowhead Pharmaceuticals sought approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) and from the local Ethics Committee to proceed with a…
Read More...

Clinical-stage biotechnology company, Aravive Biologics, Inc aiming to focus on development of treatments for Cancer and fibrotic diseases declared the commencement of  Phase 1 clinical…
Read More...

Arrowhead Pharmaceuticals seeks FDA's orphan drug designation to ARO-AAT.  Arrowhead’s second-generation investigational medicine for the treatment of a rare genetic liver disease…
Read More...

Banyan Biomarkers asserted that the U.S FDA has extended De Novo request for the commercialization of Banyan BTI Brain Trauma Indicator), an in vitro diagnostic blood test to aid in the…
Read More...

Celgene Corporation asserted that data from a randomized, placebo-controlled, multi-center, phase II clinical trial of apremilast in patients with active ulcerative colitis who had…
Read More...

Arterys Inc declared its fifth 510 (k) clearance for Arterys Oncology AI suite and is milestone indicative of the company's momentum in applying AI to further medical imaging accuracy…
Read More...

Applied artificial intelligence healthcare company, Viz.ai asserted that the US FDA has extended a De Novo request for the first-ever Computer -Aided Triage and Notification Platform to…
Read More...

DreaMed Diabetes asserted that it received CE Mark for the Advisor Pro decision-support platform for assisting healthcare professionals in the management of Type 1 diabetes. DreaMed…
Read More...

Evofem Biosciences aiming to meet women's unmet healthcare needs asserted completion of enrollment in its Phase 3 Clinical Trial evaluating Amphora vaginal gel for the prevention of…
Read More...

Citius Pharmaceuticals emphasizing on adjunctive cancer care and critical care drug products affirmed the enrollment of first patient into the Mino-Lok Phase 3 Clinical Trial for…
Read More...

Eisai declared positive results of Phase 3 study for its discovered and developed anticancer agent lenvatinib mesylate in patients grappling with unresectable hepatocellular carcinoma…
Read More...

Merck KGaA, Darmstadt, Germany, and Pfizer assert results from the Phase III JAVELIN Lung 200 trial comparing avelumab to docetaxel in patients with unresectable, recurrent or…
Read More...